Genetic effects versus bias for candidate polymorphisms in myocardial infarction: Case study and overview of large-scale evidence

American Journal of Epidemiology

Volumn 165, Issue 9, 2007, Pages 973-984

  Ntzani, Evangelia E ^a   Rizos, Evangelos C ^b   Ioannidis, John P A ^a,c,d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; AT1R; Bias (epidemiology); Epidemiology; Genes; Meta analysis; Myocardial infarction; Polymorphism, genetic

Indexed keywords

ALLELE; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; GENETIC ANALYSIS; META-ANALYSIS; POLYMORPHISM; RACE; RISK FACTOR;

ALLELE; ANGIOTENSIN 1 RECEPTOR GENE; CARDIOVASCULAR RISK; CAUCASIAN; CORONARY ARTERY DISEASE; DATA ANALYSIS; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOME; GNETOPHYTA; HEART INFARCTION; HEREDITY; HUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ALLELES; BIAS (EPIDEMIOLOGY); CORONARY ARTERIOSCLEROSIS; ETHNIC GROUPS; GREECE; HUMANS; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK FACTORS;

EID: 34247147948     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwk085     Document Type: Review

References (66)

1. Fischer M, Broeckel U, Holmer S, et al. Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. Circulation 2005;111:855-62.
2. Yang Q, Khoury MJ, Friedman J, et al. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005;34:1129-37.
3. Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
4. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet 2001;29:306-9.
5. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651-8.
6. Wheeler JG, Keavney BD, Watkins H, et al. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-95.
7. Ioannidis JP, Trikalinos TA, Ntzani EE, et al. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-71.
8. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesized associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000;355:434-42.
9. Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 2005;37:413-17.
10. Palmer LJ, Cardon LR. Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet 2005;366:1223-34.
11. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38:68-74.
12. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
13. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
15. Ioannidis JP, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative meta-analyses. Proc Natl Acad Sci U S A 2001;98:831-6.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
17. Cappelleri JC, Ioannidis JP, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996;276:1332-8.
18. Schaid DJ, Jacobsen SJ. Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol 1999;149:706-11.
19. Ioannidis JP, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 2006;164:609-14.
20. Pan ZL, Trikalinos TA, Kavvoura FK, et al. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005;2:e334.
21. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, et al. The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction. Atherosclerosis 1999;145:293-300.
22. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000;20:484-92.
23. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-47.
24. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005;111:278-87.
25. Casas JP, Bautista LE, Humphries SE, et al. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004;109:1359-65.
26. Chiodini BD, Barlera S, Franzosi MG, et al. APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis 2003;167:355-66.
27. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31.
28. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-7.
29. Cornelis MC, El-Sohemy A, Kabagambe EK, et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295:1135-41.
30. Ioannidis JP, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004;36:1312-18.
31. Sie MP, Sayed-Tabatabaei FA, Oei HH, et al. Interleukin 6-174 g/c promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 2006;26:212-17.
32. Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet 1991;337:867-72.
33. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
34. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, et al. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet Genomics 2006;16:705-11.
35. Jais PH. How frequent is altered gene expression among susceptibility genes to human complex disorders? Genet Med 2005;7:83-96.
36. Pende A, Giacche M, Castigliola L, et al. Characterization of the binding of the RNA-binding protein AUF1 to the human AT 1 receptor mRNA. Biochem Biophys Res Commun 1999;266:609-14.
37. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56:2173-80.
38. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, et al. Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin Genet 2001;60:52-7.
39. Stangl K, Cascorbi I, Stangl V, et al. A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. Am Heart J 2000;140:170-5.
40. Chiodini BD, Lewis CM. Meta-analysis of 4 coronary heart disease genome-wide linkage studies confirms a susceptibility locus on chromosome 3q. Arterioscler Thromb Vasc Biol 2003;23:1863-8.
41. Ioannidis JPA. Why most published research findings are false. PLoS Med 2005;2:e124.
42. Ioannidis JP, Gwinn M, Little J, et al. A roadmap for efficient and reliable human genome epidemiology. Nat Genet 2006;38:3-5.
43. Williams SM, Haines JL, Moore JH. The use of animal models in the study of complex disease: all else is never equal or why do so many human studies fail to replicate animal findings? Bioessays 2004;26:170-9.
44. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
45. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005;6:287-98.
46. Ioannidis JP. Commentary: grading the credibility of molecular evidence for complex diseases. Int J Epidemiol 2006;35:572-8.
47. Ozisik K, Misirlioglu M, Ulus TA, et al. Renin-angiotensin system polymorphisms and coronary artery surgery patients. Asian Cardiovasc Thorac Ann 2005;13:153-6.
48. Buraczynska M, Pijanowski Z, Spasiewicz D, et al. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiol Pol 2003;58:1-9.
49. Jones A, Dhamrait SS, Payne JR, et al. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension 2003;42:500-6.
50. Hindorff LA, Heckbert SR, Tracy R, et al. Angiotensin II type 1 receptor polymorphisms in the Cardiovascular Health Study: relation to blood pressure, ethnicity, and cardiovascular events. Am J Hypertens 2002;15:1050-6.
51. Ermis C, Tsai MY, Hanson NQ, et al. Angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensinogen polymorphisms and early myocardial infarction in Turkish population. Thromb Haemost 2002;88:693-4.
52. Hooper WC, Dowling NF, Wenger NK, et al. Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-Americans. Am J Hematol 2002;70:1-8.
53. Olivieri O, Stranieri C, Girelli D, et al. Homozygosity for angiotensinogen 235T variant increases the risk of myocardial infarction in patients with multi-vessel coronary artery disease. J Hypertens 2001;19:879-84.
54. Aoki S, Mukae S, Itoh S, et al. Genetic background in patients with acute myocardial infarction. Jpn Heart J 2001;42:15-28.
55. Steeds RP, Wardle A, Smith PD, et al. Analysis of the postulated interaction between the angiotensin II sub-type 1 receptor gene A1166C polymorphism and the insertion/deletion polymorphism of the angiotensin converting enzyme gene on risk of myocardial infarction. Atherosclerosis 2001;154:123-8.
56. Batalla A, Alvarez R, Reguero JR, et al. Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction. Clin Chem 2000;46:1910-15.
57. Surber R, Sigusch HH, Lehmann MH, et al. Angiotensin II type I receptor gene polymorphism is associated with the severity but not prevalence of coronary artery disease. Clin Genet 2000;58:237-8.
58. Canavy I, Henry M, Morange PE, et al. Genetic polymorphisms and coronary artery disease in the South of France. Thromb Haemost 2000;83:212-16.
59. Fatini C, Abbate R, Pepe G, et al. Searching for a better assessment of the individual coronary risk profile. Eur Heart J 2000;21:633-8.
60. Kee F, Morrison C, Poirier O, et al. Angiotensin II type-1 receptor and ACE polymorphisms and risk of myocardial infarction in men and women. Eur J Clin Invest 2000;30:1076-82.
61. Gardemann A, Nguyen QD, Humme J, et al. Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases. Eur Heart J 1998;19:1657-65.
62. Bogaty P, Robitaille NM, Solymoss S, et al. Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina. Am Heart J 1998;136:884-93.
63. Berge KE, Bakken A, Bohn M, et al. A DNA polymorphism at the angiotensin II type 1 receptor (AT1R) locus and myocardial infarction. Clin Genet 1997;52:71-6.
64. Nakauchi Y, Suehiro T, Yamamoto M, et al. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease. Atherosclerosis 1996;125:161-9.
65. Tiret L, Bonnardeaux A, Poirier O, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-13.
66. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C → T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005;331:1053.